PCSA

+ Watchlist + Portfolio

Processa Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.15
52-Week Range: $1.67 – $14.25
Market Cap: $7.19M
P/E (TTM): 3.30
EPS (TTM): 0.65
Dividend Yield: —

Advanced Metrics

Price/Book: 2.26
PEG Ratio: —
Return on Equity: -464.99%
Return on Assets: -193.89%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.98
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-6.96M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.99M

PCSA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.49M	$5.80M	$7.27M	$7.81M
Selling, General & Admin	$8.76M	$5.66M	$4.78M	$6.18M
Operating Expenses	$20.26M	$11.46M	$12.05M	$13.99M
Operating Income	-$20.26M	-$11.46M	-$12.05M	-$13.99M
EBITDA	-$19.47M	-$11.46M	-$12.05M	-$13.99M
Pretax Income	-$27.42M	-$11.12M	-$11.85M	-$13.56M
Income Tax	$0.00	$0.00	—	$0.00
Net Income	-$27.42M	-$11.12M	-$11.85M	-$13.56M
Diluted EPS	-851.25	-212.00	-96.78	-10.36
Diluted Shares	32219	52462	122438	1.31M

PCSA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$6.50M	$4.71M	$1.19M	$5.54M
Receivables	$0.00	—	—	—
Current Assets	$8.39M	$5.63M	$1.88M	$5.67M
Total Assets	$8.62M	$5.79M	$3.23M	$7.81M
Current Liabilities	$998.56K	$730.58K	$1.53M	$2.24M
Total Debt	$229.45K	$150.55K	$73.51K	$0.00
Total Liabilities	$1.15M	$797.48K	$1.53M	$2.24M
Retained Earnings	-$64.25M	-$75.37M	-$87.22M	-$100.78M
Shareholders' Equity	$7.47M	$4.99M	$1.70M	$5.58M
Working Capital	$7.39M	$4.90M	$346.52K	$3.43M

PCSA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$9.61M	-$8.06M	-$11.25M	-$11.39M
Capital Expenditure	—	-$2.78K	-$3.24K	-$850.00K
Free Cash Flow	-$9.61M	-$8.07M	-$11.25M	-$12.24M
Depreciation & Amortisation	$788.50K	$222.00	$782.00	$1.20K
Stock-Based Compensation	$8.83M	$1.06M	$629.51K	$857.55K
Investing Cash Flow	$0.00	-$2.78K	-$3.24K	-$850.00K
Financing Cash Flow	-$388.84K	$6.27M	$7.73M	$16.58M
Share Repurchases	-$388.84K	$0.00	-$15.90K	-$10.40K
Net Change in Cash	-$9.99M	-$1.80M	-$3.51M	$4.35M

PCSA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.59M	$2.45M	$1.66M	$2.11M	$1.81M
Selling, General & Admin	$1.26M	$1.50M	$1.83M	$1.59M	$1.52M
Operating Expenses	$2.85M	$3.95M	$3.49M	$3.70M	$3.33M
Operating Income	-$2.85M	-$3.95M	-$3.49M	-$3.70M	-$3.33M
EBITDA	-$2.85M	-$3.95M	-$3.49M	-$3.70M	-$3.33M
Pretax Income	-$2.83M	-$3.93M	-$3.44M	-$3.36M	-$3.38M
Income Tax	$0.00	—	—	—	$0.00
Net Income	-$2.83M	-$3.93M	-$3.44M	-$3.36M	-$3.38M
Diluted EPS	-7.58	-6.25	-1.75	—	-1.29
Diluted Shares	373967	622772	1.90M	—	2.62M

PCSA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.90M	$6.94M	$6.31M	$5.54M	$1.69M
Current Assets	$3.76M	$7.15M	$6.59M	$5.67M	$1.94M
Total Assets	$4.81M	$8.18M	$7.58M	$7.81M	$4.52M
Current Liabilities	$1.28M	$2.07M	$1.75M	$2.24M	$1.98M
Total Debt	$49.66K	$25.58K	$0.00	$0.00	—
Total Liabilities	$1.28M	$2.07M	$1.75M	$2.24M	$1.98M
Retained Earnings	-$90.05M	-$93.99M	-$97.42M	-$100.78M	-$104.16M
Shareholders' Equity	$3.53M	$6.11M	$5.83M	$5.58M	$2.54M
Working Capital	$2.47M	$5.08M	$4.84M	$3.43M	-$41.69K

PCSA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.73M	-$2.27M	-$3.48M	-$2.90M	-$3.59M
Free Cash Flow	-$2.73M	-$2.27M	-$3.48M	-$3.75M	-$3.59M
Depreciation & Amortisation	$301.00	$301.00	$301.00	$301.00	$301.00
Stock-Based Compensation	$227.71K	$203.25K	$303.05K	$123.54K	$95.96K
Investing Cash Flow	$0.00	—	—	-$850.00K	-$500.00K
Financing Cash Flow	$4.44M	$6.31M	$2.86M	$2.98M	$244.78K
Share Repurchases	-$1.44K	-$8.96K	$0.00	$0.00	-$320.00
Net Change in Cash	$1.71M	$4.04M	-$628.20K	-$771.47K	-$3.85M

Market Snapshot

About

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for patients with unmet medical needs in oncology and other therapeutic areas. The company employs a regulatory pathway strategy using its Next Generation Chemotherapy (NGC) platform to advance drug candidates through clinical development more efficiently. Processa has a pipeline of product candidates targeting various cancers and rare diseases. The company is based in Hanover, Maryland, and seeks to bring innovative treatments to market through partnerships and strategic development approaches.